Industry Educational Session - Evolving treatment choices for patients with LBCL - Sponsored by Bristol Myers Squibb UK & Ireland
Tracks
-
| Sunday, April 27, 2025 |
| 1:25 PM - 2:10 PM |
| Carron 1 |
Details
The session objectives are:
• To discuss how the advancement of treatment choices for large B-cell lymphoma (LBCL) impacts clinicians and patients.
• To build confidence in clinical decision making in the evolving treatment landscape.
• To explore themes including appropriate patient selection and referral, as well as toxicity monitoring.
This promotional symposium is sponsored by Bristol Myers Squibb and intended for UK healthcare professionals only. Bristol Myers Squibb products will be discussed in this symposium. Prescribing and adverse event reporting information will be available at the meeting.
2009-GB-2400027 | March 2025
Speaker
Prof. Andrew Davies
Professor Of Haematological Oncology
University of Southampton
- Professor of Haematological Oncology, University Hospital Southampton NHS Foundation Trust, UK (Chair)
Prof Dr med Bertram Glaß
Helios Hospital Berlin-Buch, Germany
- Chief Physician Haematology & Stem Cell Therapy, Helios Hospital Berlin-Buch, Germany
Dr. Wendy Osborne
Consultant
Freeman Hospital Newcastle
-Consultant Haematologist at the Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust
